CATALOGO DEI PRODOTTI DELLA RICERCA

Milella, Michele
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.829
EU - Europa 4.152
AS - Asia 1.515
SA - Sud America 21
AF - Africa 10
Continente sconosciuto - Info sul continente non disponibili 7
OC - Oceania 7
AN - Antartide 1
Totale 10.542
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.775
CN - Cina 1.287
GB - Regno Unito 787
FR - Francia 756
IE - Irlanda 689
IT - Italia 589
SE - Svezia 551
DE - Germania 363
FI - Finlandia 242
UA - Ucraina 68
VN - Vietnam 62
CA - Canada 49
KR - Corea 37
PL - Polonia 24
IN - India 21
TH - Thailandia 21
HK - Hong Kong 20
IR - Iran 15
NL - Olanda 15
SG - Singapore 14
BE - Belgio 12
JP - Giappone 9
AT - Austria 8
AU - Australia 7
CH - Svizzera 7
EG - Egitto 7
ES - Italia 7
EU - Europa 7
RU - Federazione Russa 7
PE - Perù 6
TR - Turchia 6
CL - Cile 5
LU - Lussemburgo 5
BR - Brasile 4
CZ - Repubblica Ceca 4
MK - Macedonia 4
CO - Colombia 3
IL - Israele 3
RO - Romania 3
AM - Armenia 2
AZ - Azerbaigian 2
BG - Bulgaria 2
BY - Bielorussia 2
CR - Costa Rica 2
DK - Danimarca 2
EC - Ecuador 2
ID - Indonesia 2
KG - Kirghizistan 2
KH - Cambogia 2
MX - Messico 2
MY - Malesia 2
PH - Filippine 2
PK - Pakistan 2
AE - Emirati Arabi Uniti 1
DO - Repubblica Dominicana 1
FK - Isole Falkland (Malvinas) 1
GR - Grecia 1
GS - Georgia del Sud e Isole Sandwich Australi 1
HR - Croazia 1
KZ - Kazakistan 1
LV - Lettonia 1
NO - Norvegia 1
PT - Portogallo 1
SA - Arabia Saudita 1
SC - Seychelles 1
TN - Tunisia 1
UZ - Uzbekistan 1
ZA - Sudafrica 1
Totale 10.542
Salva come PNG Salva come JPEG
Città #
Chandler 1.264
Southend 738
Dublin 668
Woodbridge 333
Jacksonville 299
Beijing 288
Ashburn 272
Lawrence 267
Princeton 267
Verona 227
Ann Arbor 197
Sindelfingen 185
Houston 170
Redmond 139
Wilmington 135
Jinan 132
New York 106
Helsinki 104
Nanjing 84
Shenyang 74
Hebei 61
Seattle 59
Tianjin 48
Ningbo 44
Milan 43
Toronto 39
Seoul 37
Changsha 35
Haikou 31
Zhengzhou 30
Dong Ket 29
Hangzhou 29
Nanchang 29
Washington 26
Redwood City 25
Taiyuan 25
Taizhou 25
Jiaxing 22
Bangkok 21
Fuzhou 21
Andover 20
Guangzhou 20
Lanzhou 20
Los Angeles 20
Chicago 17
Dongguan 16
Rome 16
San Francisco 15
Fairfield 14
Hong Kong 14
Lappeenranta 13
Brussels 12
Falls Church 12
Norwalk 11
Bologna 10
Cambridge 9
Zanjan 9
Boardman 8
Falkenstein 8
Huskvarna 8
Singapore 8
Amsterdam 7
Boydton 7
Chions 7
Clearwater 7
Este 7
Kochi 7
Laurel 7
Trento 7
Dearborn 6
Isola della Scala 6
Lima 6
London 6
Mehlingen 6
Menlo Park 6
Pieve di Soligo 6
Vienna 6
Bussolengo 5
Frankfurt am Main 5
Padova 5
Palermo 5
Paris 5
Tokyo 5
Henderson 4
Lille 4
Lozzo Atestino 4
Montréal 4
Mumbai 4
San Diego 4
Sydney 4
Cairate 3
Duncan 3
Genoa 3
Leawood 3
Munich 3
Neiva 3
Novokuznetsk 3
Sant'Ambrogio di Valpolicella 3
Somerville 3
Tanta 3
Totale 7.100
Salva come PNG Salva come JPEG
Nome #
Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers 113
Immunoevolution of mouse pancreatic organoid isografts from preinvasive to metastatic disease 111
An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer 100
Genomic characterization of hepatoid tumors: context matters 100
Autoantibodies to Ezrin are an early sign of pancreatic cancer in humans and in genetically engineered mouse models 97
Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma 95
Emerging pathways and future targets for the molecular therapy of pancreatic cancer. 92
ERK 1/2 phosphorylation is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia 91
An integrated humoral and cellular response is elicited in pancreatic cancer by alpha-enolase, a novel pancreatic ductal adenocarcinoma-associated antigen 84
Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models 84
PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer 83
Adjuvant Chemotherapy For Resected Non-Small-Cell Lung Cancer: Future Perspectives For Clinical Research 82
Organisational challenges, volumes of oncological activity and patients' perception during the severe acute respiratory syndrome coronavirus 2 epidemic 81
"Running with cancer": A qualitative study to evaluate barriers and motivations in running for female oncological patients 80
Deep vein thrombosis in SARS-CoV-2 pneumonia-affected patients within standard care units: exploring a submerged portion of the iceberg. 79
Adjuvant treatment for resected renal cell carcinoma: are all strategies equally negative? Potential implications for trial design with targeted agents. 74
A phase II study of liposomal irinotecan with 5-fluorouracil, leucovorin and oxaliplatin in patients with resectable pancreatic cancer: the nITRO trial 72
Anti-Angiogenic Drugs and Biomarkers in Non-Small-Cell Lung Cancer: A 'Hard Days Night' 71
Single-agent vinorelbine in pretreated breast cancer patients: comparison of two different schedules 71
Adjuvant treatment for resected renal cell carcinoma: are all strategies equally negative? Potential implications for trial design with targeted agents. 71
Circulating autoantibodies to phosphorylated alpha-enolase are a hallmark of pancreatic cancer 70
Risk Stratification Model for Resected Squamous-Cell Lung Cancer Patients According to Clinical and Pathological Factors 70
Long-Term Patient-Centred Follow-up in a Prospective Cohort of Patients with COVID-19 70
An Italian study on treatment trends and outcomes of patients with stage III pancreatic adenocarcinoma in the gemcitabine era: is it time to change? 69
Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma 68
Emerging pathways and future targets for the molecular therapy of pancreatic cancer. 68
Advances towards the design and development of personalized non-small-cell lung cancer drug therapy. 67
From Genetic Alterations to Tumor Microenvironment: The Ariadne's String in Pancreatic Cancer 66
Prognostic Impact of Preoperative Nutritional Risk in Patients Who Undergo Surgery for Pancreatic Adenocarcinoma 65
Immune landscape, evolution, hypoxia-mediated viral mimicry pathways and therapeutic potential in molecular subtypes of pancreatic neuroendocrine tumours 64
Integrating supportive care into the multidisciplinary management of lung cancer: we can't wait any longer 64
Prognostic Model for Resected Squamous-Cell Lung Cancer: External Multicenter Validation and Propensity Score Analysis exploring the Impact of Adjuvant and Neoadjuvant Treatment 62
Role of next-generation genomic sequencing in targeted agents repositioning for pancreaticoduodenal cancer patients 62
Sequential therapy in metastatic clear cell renal carcinoma: TKI-TKI vs TKI-mTOR. 61
Novel Clinical Prognostic Score Incorporating the Number of Resected Lymph-Nodes to Predict Recurrence and Survival in Non-Small-Cell Lung Cancer. 61
Clinical Evaluation of the Use of Exemestane as Further Hormonal Therapy after Nonsteroidal Aromatase Inhibitors in Postmenopausal Metastatic Breast Cancer Patients 61
Hypofractionated Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost and Simultaneous Integrated Protection in Pancreatic Ductal Adenocarcinoma 61
Adjuvant Chemotherapy for Non-Small-Cell Lung Cancer 61
The pattern of hMENA isoforms is regulated by TGF-β1 in pancreatic cancer and may predict patient outcome 60
The Italian Rare Pancreatic Exocrine Cancer Initiative 60
Do immune checkpoint inhibitors need new studies methodology? 60
Aromatase inhibitors in post-menopausal metastatic breast carcinoma 59
PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine. 58
Cardiotoxicity and Incidence Of Brain Metastases After Adjuvant Trastuzumab for Early Breast Cancer: The Dark Side of the Moon? A Meta-Analysis of The Randomized Trials. 58
Capecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancers. 57
Metastatic pancreatic cancer: Is there a light at the end of the tunnel? 57
Unmasking the impact of Rictor in cancer: novel insights of mTORC2 complex 57
Multidisciplinary lifestyle intervention to manage pancreatic cancer-related cachexia: a case report 57
JAK/Stat5-mediated subtype-specific lymphocyte antigen 6 complex, locus G6D (LY6G6D) expression drives mismatch repair proficient colorectal cancer 56
Muscle derangement and alteration of the nutritional machinery in NSCLC 56
Molecular predictors of EGFR-mutant NSCLC transformation into LCNEC after frontline osimertinib: digging under the surface 55
Risk Adapted Ablative Radiotherapy After Intensive Chemotherapy for Locally Advanced Pancreatic Cancer 55
Prognostic impact of alternative splicing-derived hMENA isoforms in resected, node-negative, non-small-cell lung cancer. 54
Lack of growth inhibitory synergism with combined MAPK/PI3K inhibition in preclinical models of pancreatic cancer 54
Autoantibody signature in human ductal pancreatic adenocarcinoma 54
PTEN in Lung Cancer: Dealing with the Problem, Building on New Knowledge and Turning the Game Around 54
Physical activity and exercise in lung cancer care: will promises be fulfilled? 53
Liquid Biopsy as Surrogate for Tissue for Molecular Profiling in Pancreatic Cancer: A Meta-Analysis Towards Precision Medicine 53
Evaluation of nutritional status in non-small-cell lung cancer: screening, assessment and correlation with treatment outcome 53
Characterization of Myeloid-derived Suppressor Cells in a Patient With Lung Adenocarcinoma Undergoing Durvalumab Treatment: A Case Report 52
Pan-cancer analysis of whole genomes 52
Exercise prehabilitation in lung cancer: Getting stronger to recover faster 52
Alternative Lengthening of Telomeres (ALT) in Pancreatic Neuroendocrine Tumors: Ready for Prime-Time in Clinical Practice? 52
Multicenter Retrospective Analysis of Second-Line Therapy after Gemcitabine Plus Nab-Paclitaxel in Advanced Pancreatic Cancer Patients 52
New aromatase inhibitors as second-line endocrine therapy in postmenopausal patients with metastatic breast carcinoma 51
Signal transduction pathways as therapeutic targets in cancer therapy 50
First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer. 50
PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine. 50
Factors influencing physical activity in cancer patients during oncological treatments: a qualitative study 50
Psychological impact of Covid-19 pandemic on oncological patients: a survey in Northern Italy 50
IL CARCINOMA POLMONARE A GRANDI CELLULE 49
Outcome of advanced NSCLC patients harbouring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment. A meta-analysis. 49
Risk and severity of SARS-CoV-2 infection in breast cancer patients undergoing a structured infection screening program at the University and Hospital Trust of Verona 49
Progression-free survival as primary endpoint in randomized clinical trials of targeted agents for advanced renal cell carcinoma. Correlation with overall survival, benchmarking and power analysis. 48
ASO Author Reflections: Preoperative Nutritional Care: The 'Cinderella' of Surgical Management in Patients with Pancreatic Cancer 48
Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort 48
Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Pancreatic Cancer: Systematic Review and Still-Open Questions 48
Open radiofrequency ablation as upfront treatment for locally advanced pancreatic cancer: Requiem from a randomized controlled trial 48
Clinical outcomes in patients with metastatic renal cell carcinoma receiving everolimus or temsirolimus after sunitinib 47
Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples 47
mTOR Cross-Talk in Cancer and Potential for Combination Therapy. 47
Exercise levels and preferences in cancer patients: a cross-sectional study 47
MDM2 gene amplification as selection tool for innovative targeted approaches in PD-L1 positive or negative muscle-invasive urothelial bladder carcinoma 47
Morphologic and Molecular Landscape of Pancreatic Cancer Variants as the Basis of New Therapeutic Strategies for Precision Oncology 47
Infections and Immunotherapy in Lung Cancer: A Bad Relationship? 47
Targeting KRAS: The Elephant in the Room of Epithelial Cancers 47
Fixed dose-rate gemcitabine infusion as first-line treatment for advanced-stage carcinoma of the pancreas and biliary tree 46
Magnitude of Benefit of Adjuvant Chemotherapy for Non-Small-Cell Lung Cancer: Meta-Analysis of Randomized Clinical Trials. 46
KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities 46
Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials 45
Comprehensive analysis of 34 MiT family translocation renal cell carcinomas and review of the literature: investigating prognostic markers and therapy targets 45
A phase II trial proposal of total neoadjuvant treatment with primary chemotherapy, stereotactic body radiation therapy, and intraoperative radiation therapy in borderline resectable pancreatic adenocarcinoma 45
Nurses' perspectives on physical activity promotion in cancer patients: A qualitative research 45
Treatment trends in metastatic pancreatic cancer patients: Is it time to change? 44
Is cardiac troponin T serum level an accurate surrogate for acute doxorubicin-related myocardial injury? 44
Does hormone treatment added to radiotherapy improve outcome in locally advanced prostate cancer? Meta-analysis of randomized trials. 44
Do adjuvant aromatase inhibitors increase the cardiovascular risk in post-menopausal women with early breast cancer? Meta-analysis of randomized trials 44
Second- and third-generation aromatase inhibitors as first-line endocrine therapy in postmenopausal metastatic breast cancer patients: a pooled analysis of the randomised trials 44
Nuclear and cytoplasmic cellular distribution of survivin as survival predictor in resected non-small-cell lung cancer. 44
The actin modulator hMENA regulates GAS6-AXL axis and pro-tumor cancer/stromal cell cooperation 44
Totale 6.031
Salva come PNG Salva come JPEG
Categoria #
all - tutte 50.210
article - articoli 49.742
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 468
Totale 100.420
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201945 0 0 0 0 0 0 0 0 0 4 8 33
2019/2020618 93 26 31 20 47 50 38 36 52 51 57 117
2020/20211.111 93 259 52 122 146 119 37 34 43 25 110 71
2021/20221.789 110 378 60 108 46 22 37 103 59 37 310 519
2022/20234.070 290 364 383 714 323 1.057 61 223 440 49 105 61
2023/20242.012 91 167 234 360 225 356 206 191 56 126 0 0
Totale 10.946